Sale Of Ranbaxy Feeds Idea Japan Firms Not Good At Foreign Deals
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo's bailout from its $4.7 billion purchase of Ranbaxy Laboratories six years ago has served to support a perception of Japan companies being weak in making deals outside of their own country.